At the news
? NEUTRALIMPACT 4/10 6-K filed Nov 9, 2026 at 07:01 ET
Compugen reported Q3 2026 net loss of $5.8M ($0.06 per share), narrower than the $7.0M loss in Q3 2025, on revenue of $3.8M (up from $1.9M). The EPS of -$0.06 beat the consensus estimate of -$0.09. Cash of $117.5M is expected to fund operations into 2029. Key pipeline catalysts include MAIA-ovarian results by end of Q1 2027 and Phase 3 rilvegostomig data from AstraZeneca in H2 2027.
- Q3 2026 net loss of $5.8M ($0.06 per share) vs $7.0M ($0.07) in Q3 2025
- Revenue of $3.8M vs $1.9M in Q3 2025, driven by Gilead license revenue recognition
- Cash and equivalents of $117.5M as of Sep 30, 2026; runway into 2029
- MAIA-ovarian trial (COM701) fully enrolled; results expected by end of Q1 2027
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access